Denosumab

From Wikipedia, the free encyclopedia

Denosumab?
Therapeutic monoclonal antibody
Source	Human
Target	?
Identifiers
CAS number	?
ATC code	?
PubChem	?
Chemical data
Formula	?
Mol. mass	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Denosumab (formerly known as AMG 162) is a human monoclonal antibody which is being studied[1] in the treatment of osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma.

Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal. In many bone loss conditions, RANKL overwhelms the body's natural defense against bone destruction. Denosumab therefore mimicks the endogenous effects of osteoprotegerin.

[edit] External links

• Denosumab in Postmenopausal Women with Low Bone Mineral Density - free full-text

v • d • e Human monoclonal antibodies ("-u-") "-limu-" (immune system) immunosuppression: Adalimumab, Atorolimumab, Gantenerumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab, Ziralimumab immune activation: Ipilimumab, Tremelimumab other: Bertilimumab "-kinu-" (interleukin as target) Canakinumab "-tumu-" (cancer immunotherapy) Adecatumumab, Anetumumab, Belimumab, Duntumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Ofatumumab, Panitumumab, Pritumumab, Votumumab, Zalutumumab, Zanolimumab "-osu-" (bone) Denosumab "-mulu-" (musculoskeletal) Durimulumab, Durmulumab, Stamulumab "-fungu-" (fungal) Efungumab "-viru-" (viral) Exbivirumab, Libivirumab, Regavirumab, Sevirumab, Tuvirumab "-bacu-" (bacterial) Nebacumab, Raxibacumab